Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
06660 AIM VACCINE
22.950+0.350+1.55%
Trading Session
02/01 14:49 CCT
High
22.950
Open
22.500
Turnover
1.59M
Low
22.250
Pre Close
22.600
Volume
70.80K
Price Forecast
News
Comment
AIM Vaccine Raises Nearly $3 Million From Partial Exercise of Hong Kong IPO's Overallotment Option
AIM Vaccine Raises Nearly $3 Million From Partial Exercise of Hong Kong IPO's Overallotment Option
04:47 AM EDT, 10/31/2022 (MT Newswires) -- AIM Vaccine (HKG:6660) said the overallotment option of its Hong Kong IPO was partially exercised by its underwriters on Oct. 28. The vaccine maker will iss
China OKs Trial for AIM Vaccine Unit's Hand, Foot, and Mouth Disease Vaccine Candidate; Shares Rise 3%
11:55 PM EDT, 10/30/2022 (MT Newswires) -- China's medical products regulator approved AIM Vaccine (HKG:6660) unit AIM Kanghuai Biopharmaceutical's clinical trial for its vaccine candidate for hand, f
China Approves Clinical Trial for AIM Vaccine Unit's Human Rabies Vaccine
09:47 PM EDT, 10/23/2022 (MT Newswires) -- China's medical products regulator approved a clinical trial for AIM Vaccine's (HKG:6660) freeze-dried human rabies vaccine candidate, according to a Monday
Emmy Vaccine [06660] is now at HK $19.80, an increase of 18.14%
As of 09:35, Emmy Vaccine [06660] was at HK $19.80, up 3.04 Hong Kong dollars or 18.14% from yesterday's closing price, with a turnover of HK $845200, with a high price of HK $19.8 today and a lowest price of HK $17.50. According to yesterday's closing price, the 10-day average price was HK $0.00, the 50-day average price was HK $0.00, the current price-earnings ratio was-22.99, and the 14-day strength index was 0.00.
IPO Trends of Hong Kong stocks: 2350.HK listed today
2350 Gelonghui Sept. 26 (02350.HK) $listed today, $06678.HK (06678.HK) $, $Emmy Vaccine (06660.HK) $, $03931.HK (03931.HK) $, $GC CONSTRUCTION (01489.HK) $and $Jianshi Technology-B (09877.HK) $are in the application period.
No More
Company Overview
More
Le Meridien Vaccine is a large-scale private vaccine group with a full industry chain in China. Its business covers the entire industry value chain from R&D to manufacturing to commercialization. It obtained batches of about 60 million doses in 2020, achieving sales of vaccine products to 31 provinces, autonomous regions and municipalities directly under the Central Government of China. Le Meridien has five vaccine companies that have proven human vaccine platform technology, which greatly guarantees the speed and flexibility of the company's development. Currently, the company has 8 commercial vaccines for 6 disease fields and 23 innovative vaccines under development for 13 disease fields. The products in production and development cover all of the world's top ten vaccine products (based on global sales in 2020).
Through ten years of development, the company has developed an inclusive and pioneering business model and corporate culture, through which it has been able to continuously expand and optimize its existing business. Currently, four licensed vaccine manufacturers are wholly owned, namely Le Meridien, Emmy Conhuai, Emmy Weixin, and Rongan Biotech. It owns 3 research institutes, of which the R&D center, Le Meridien Explorer, which was built in 2018, focuses on providing technical support for early and cutting-edge research by R&D departments in various factories. Le Meridien acquired Zhuhai Lifanda Biotechnology Co., Ltd. in 2021. The company is one of only 3 domestic companies to obtain approval for clinical trials of the mRNA COVID-19 vaccine, and has an independent mRNA production and drug delivery technology platform.
Le Meridien Vaccine Group has always adhered to the mission of “making vaccines of conscience and living a healthy world” and strictly controls the quality of vaccines. The company is equipped with a professional and dedicated sales team composed of more than 100 members with an average of more than 10 years of experience in drug or vaccine sales. The core business leadership team has an average of 12 years of vaccine commercialization experience for multinational pharmaceutical companies, and has excellent results in marketing major international vaccines (including the world's first HPV, IPV, and dTAP-IPV-Hib). The products currently on sale mainly include recombinant hepatitis B vaccine (Hanson's yeast), freeze-dried human rabies vaccine (Vero cells), hepatitis A inactivated vaccine (human diploid cells), live attenuated mumps vaccine, bivalent renal syndrome hemorrhagic fever inactivated vaccine (Vero cells), and ACYW135 group meningococcal polysaccharide vaccine (MPSV4).
CEO： Yan Zhou
Market： Hong Kong motherboard
Listing Date： 10/06/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet